Cargando…
Chimeric antigen receptor T cell: A cancer immunotherapy
During present decade, targeted drug therapy has been the epitome for treatment of cancer. Drugs like Imatinib, a tyrosine kinase receptor inhibitor and Trastuzumab, an human epidermal growth factor receptor-2/neu inhibitor, has been developed and accepted widely for management of chronic myeloid le...
Autores principales: | Singh, Surjit, Khasbage, Sameer, Kaur, Rimple Jeet, Sidhu, Jaspreet Kaur, Bhandari, Bharti |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396692/ https://www.ncbi.nlm.nih.gov/pubmed/35848695 http://dx.doi.org/10.4103/ijp.ijp_531_20 |
Ejemplares similares
-
Flashback and lessons learnt from history of pandemics before COVID-19
por: Parihar, Shivay, et al.
Publicado: (2021) -
Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer
por: Cartellieri, Marc, et al.
Publicado: (2010) -
Chimeric antigen receptor-T cells immunotherapy for targeting breast cancer
por: Rahimmanesh, Ilnaz, et al.
Publicado: (2021) -
Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges
por: Han, Ethan Q, et al.
Publicado: (2013) -
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
por: Yilmaz, Ahmet, et al.
Publicado: (2020)